3B BlackBio Dx Limited has announced that its board meeting is scheduled to be held on Friday, May 29, 2026. The meeting will commence at 03:00 P.M. to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026.

Agenda for the Meeting

The primary agenda for the board meeting includes the consideration and approval of the Audited Financial Results, both Standalone and Consolidated, for the fourth quarter and the full financial year ending March 31, 2026. Furthermore, the board will discuss the matter of recommending a dividend, if any, for the financial year ended March 31, 2026.

Trading Window Closure

In accordance with the Company's Code of Conduct to Regulate, Monitor and Report Insider Trading, the trading window for the company's Equity Shares remains closed. This closure applies to Designated Persons and their Immediate Relatives, effective from Wednesday, April 1, 2026. The window will remain closed until 48 hours after the financial results are announced on May 29, 2026.

Meeting Details

3b blackbio dx Limited has formally declared to BSE Limited that it does not qualify as a Large Corporate under the Securities and Exchange Board of India (SEBI) regulatory framework, thereby exempting itself from specific disclosure requirements.

Updated Regulatory Compliance Declaration

The company submitted its latest declaration on April 15, 2026, addressing the non-applicability of disclosure requirements outlined in SEBI circular SEBI/HO/DDHS/DDHSRACPOD1/P/CIR/2023/172 dated October 19, 2023. The formal communication was directed to the Department of Corporate Relations at BSE Limited.

Corporate Authorization

The declaration was duly authorized and digitally signed by key company officials. Company Secretary Navneet Kaur (ACS No. 29130) and Chief Financial Officer Nikhil Kuber Dubey (DIN: 00538049) both provided their digital signatures on April 15, 2026, at 16:14:22 and 16:15:03 respectively.

SEBI Large Corporate Framework

The SEBI circular dated October 19, 2023, establishes specific criteria for categorizing companies as Large Corporates, which triggers additional disclosure obligations. By confirming its non-applicability under these criteria, 3B BlackBio Dx Limited has clarified its regulatory status and compliance obligations to the stock exchange.

The company's formal submission serves as an official record with BSE Limited, ensuring transparency regarding its regulatory classification and associated disclosure requirements under current SEBI guidelines.